Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Sponsor

Fuzhou General Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT04088110

Collaborator

(none)

Enrollment

Location

Arm

Anticipated Duration (Months)

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a single-arm, open-label, phase II study, comparing the efficacy and safety of pyrotinib plus trastuzumab and aromatase inhibitors, in the treatment of HR (hormone receptor)+/HER2 (human epidermal growth factor receptor 2) + MBC and inoperable LABC patients.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer Female HER2-positive Breast Cancer Hormone Receptor Positive Malignant Neoplasm of Breast Metastatic Breast Cancer Breast Diseases Hormone Receptor Positive Tumor	Drug: Pyrotinib Drug: Trastuzumab Drug: Aromatase Inhibitors	Phase 2

Detailed Description

This is a exploratory, single-arm, open-label,multicenter phase II trial. Our primary purpose is to compare that PFS of patients with pyrotinib plus trastuzumab and AI for HER2-positive and hormone receptor-positive MBC or locally advanced breast cancer (LABC).

In treatment period, patients will be administrated pyrotinib plus trastuzumab and aromatase inhibitors, every 21 days for 1 cycle, until disease progression, toxicity intolerance, withdrawal of informed consent, patients judged must be terminated study termination.

The imaging evaluation was performed according to the RECIST 1.1 criteria every 6 weeks.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

77 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study

Anticipated Study Start Date :

Nov 1, 2019

Anticipated Primary Completion Date :

Nov 1, 2021

Anticipated Study Completion Date :

Nov 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Pyrotinib and trastuzumab plus aromatase inhibito Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.	Drug: Pyrotinib Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle. Other Names: Study drug Drug: Trastuzumab Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses). Other Names: Herceptin® Drug: Aromatase Inhibitors The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral. Other Names: anastrozole, letrozole or exemestane

Arm

Intervention/Treatment

Experimental: Pyrotinib and trastuzumab plus aromatase inhibito

Participants will receive pyrotinib in combination with trastuzumab plus AI until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.

Drug: Pyrotinib

Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.

Other Names:

Study drug

Drug: Trastuzumab

Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).

Other Names:

Herceptin®

Drug: Aromatase Inhibitors

The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.

Other Names:

anastrozole, letrozole or exemestane

Outcome Measures

Primary Outcome Measures

Progression-Free Survival (PFS) [From randomization to 36 month]
PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. The PFS will be will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median PFS, hazard ratio with appropriate confidence intervals will be reported.

Secondary Outcome Measures

Objective Overall Response Rate (ORR) [From randomization to 36 month]
ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR. ORR was assessed by the investigator according to RECIST version 1.1 and is based on BOR, which is defined as best response recorded from start of study treatment until disease progression/recurrence or death. Participants needed to have two consecutive assessments of PR or CR to be a responder. Only participants with measurable disease at baseline were included in the analysis of BOR and who did not have any evaluable post-baseline assessments were classified as not evaluable. The ORR will be reported by percentage with each arms and appropriate confidence intervals.
Duration of Response (DoR) [From randomization to 36 month]
DoR is defined as date of initial confirmed PR/CR until date of progressive disease or death from any cause. PR or CR or SD is according to RECIST version 1.1. The DoR will be estimated using Kaplan-Meier method. Kaplan-Meier curves, median DoR, hazard ratio with appropriate confidence intervals will be reported.
Overall Survival (OS) [From randomization to 36 month]
Overall Survival (OS), defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication and participants with no post-baseline information were censored at the date of randomization. The OS will be will be estimated using Kaplan-Meier method. A Kaplan-Meier curve, median OS, hazard ratio with appropriate confidence intervals will be reported.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Age≥18 years,≤70 years, female;
Postmenopausal or pre-menopausal with ovarian function suppression;
with or without measurable lesion evaluable according to Response Evaluation Criteria In Solid Tumors Version 1.1;
Metastatic or inoperable local advanced Invasive breast cancer;
HER2-positive breast cancer;
HR-positive breast cancer;
LVEF ≥55%;QT interva<470 ms;
Eastern Cooperative Oncology Group(ECOG) scale 0-1;
Life expectancy ≥3 months;

Exclusion Criteria:

Previous systemic non-hormonal anticancer therapy in the metastatic or advanced breast cancer setting;
Received endocrine therapy within 7 days before randomization;Uncontrolled central nervous system metastases;
Disease-free interval from completion of adjuvant/neo-adjuvant systemic non-hormonal treatment to recurrence of within 6 months.
Other malignancies within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma.
Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment
Severe organ dysfunction as assessed by signs and symptoms, laboratory studies and rapid progression of disease, which leading to a clinical indication for chemotherapy.
History of CHF of any New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (exception, atrial fibrillation, paroxysmal supraventricular tachycardia);
History of myocardial infarction within 6 months of randomization;
History of LVEF decline to below 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy;
Pregnant or lactating women;
QT interval>470 ms;
Serious concomitant diseases (including severe hypertension, severe diabetes, active infection, thyroid disease, etc.) that are harmful to the patient's safety or affect the patient's completion of the study;